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The most common clinical feature of chronic graft-versus-
host disease (GVHD) is skin involvement, which is present
in 67% of patients with chronic GVHD.1 We report a case of
chronic GVHD that was caused by an implantable
cardioverter-deﬁbrillator (ICD). To our knowledge, there
have been no reported cases of this condition.Case description
We present a 55-year-old Caucasian man with ischemic
cardiomyopathy and acute myeloid leukemia, for which he
had undergone successful stem cell transplantation but which
was later complicated by chronic GVHD. He was hospi-
talized 2 months after dual-chamber ICD implantation for
concerns of pocket infection and treated with intravenous
antibiotics. His initial case of acute GVHD was several
months after his stem cell transplant and was localized to the
skin on his hands. This was successfully treated with
cyclosporine and triamcinolone cream. He subsequently
experienced chronic GVHD over 50% of his body surface,
proven by skin biopsy, with sicca syndrome and was started
on systemic steroids, which resolved his symptoms.
He was seen for an evaluation of an inﬂammatory skin
lesion overlying his ICD (Figure 1). There had not been a
deﬁnite diagnosis as to the cause of this erythema. The skin
lesion was an approximately 3  3-cm atrophic patch
directly overlying the ICD device module with mild periph-
eral erythema, prominent telangiectasias, and central honey-
colored crusting. There was no drainage, discharge, dermal
induration, or scale. The patient had negative cultures,
leukocytosis of unknown etiology, and no fevers or chills,
and was started on vancomycin and cefepime for a possible
infection of the site. A transesophageal echocardiogram wasKEYWORDS Graft-versus-host disease; Device implantation complication;
ICD; Autoimmune reaction; Post stem cell transplant
(Heart Rhythm Case Reports 2016;2:446–447)
Address reprint requests and correspondence: Dr Jack Xu, 4301
W. Markham St., Slot #634, Little Rock, AR 72205. E-mail address:
jxu@uams.edu.
2214-0271 Published by Elsevier Inc. on behalf of Heart Rhythm Society. This is
(http://creativecommons.org/licenses/by-nc-nd/4.0/).done and showed no endocarditis of the pacemaker leads. He
had already had an ICD generator change in the past without
resolution of the symptoms. He was found to have no
extravasation of white blood cells to the ICD site on white
blood cell scan. He was also found to have an irregular nevus
lateral to the pacemaker site. A shave biopsy was performed
and shown to be melanoma. He underwent wide local
excision of the melanoma lesion as well as repositioning of
the ICD underneath the left pectoralis muscle, as it was felt
that the erythema surrounding the device could be due to an
allergy to a compound of the device. The surgical pathology
showed no evidence of residual melanoma in the skin.
However, the soft tissue around the ICD did show dense
sclerosis with brisk lymphoplasmacytic inﬁltrate that was
much more robust than would be seen in the reactive soft
tissue capsule that typically surrounds implanted devices like
ICDs. Given the known history of chronic GVHD in the skin
in this patient, the pathologist interpreted the changes as most
consistent with the sclerodermoid form of chronic GVHD.
A metal allergy was a considered possibility histologicallyFigure 1 Photograph of the skin overlying the implantable cardioverter-
deﬁbrillator on the left upper chest.
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KEY TEACHING POINTS
 Graft-versus-host disease (GVHD) may manifest
over an implantable cardioverter-deﬁbrillator
implantation site.
 We believe that it is important to include GVHD
when cultures are negative and antibiotics have
not subsided symptoms, especially in a patient
who has undergone allogeneic hematopoietic cell
transplantation.
 Early diagnosis and treatment are critical to
improve outcome of GVHD.
447Xu et al Complication of Device Implantationbut was less favored, given the clinical history of extensive
chronic GVHD of the skin. Antibiotics were discontinued
and the dose of steroids was increased, with subsequent
resolution of his symptoms.
Discussion
The incidence of complications with device implantation has
been reported to be approximately 3%-6%.2 The most common
complications of device implantation are pneumothorax, infec-
tion, and device-pocket hematoma requiring evacuation.3 In a
study looking at the long-term outcome at 4 years after ICD
implantation, the most common adverse effects were infections,
lead dislodgements, and lead malfunctions.4 Chronic GVHD
is a multisystem disease that can manifest in any organ.5
However, skin and oral mucosa are the most common
manifestations of GVHD.6 GVHD manifestation in the skin
can be classiﬁed into 2 major forms: lichenoid (lichen planus–
like) or sclerodermoid (scleroderma/morphea-like) lesion.1
Chronic GVHD usually develops 4 months after transplanta-
tion, but manifestations can start appearing as early as 40 days
following transplantation.7 Chronic GVHD can occur after
previous instances of acute GVHD (32% of cases).7 GVHD can
develop spontaneously or as a result of a trigger.7 After a
thorough literature search, we do not believe that there is any
population outside of the allogeneic hematopoietic cell trans-
plant population for whom a consideration of GVHD is
relevant. There are several proposed immune-mediated mech-
anisms of this disease process, as well as several identiﬁabletriggers, including UV irradiation, physical trauma, infection
with herpes zoster, and Borellia species.7 The histologic
features of GVHD, whether in the skin or around an ICD as
in this case, are not entirely speciﬁc and must be interpreted by
the pathologist within the clinical context. The presence of
dense sclerosis with brisk inﬂammation ﬁt well with the
histologic features that are often seen in chronic GVHD of
the skin. Those features, in conjunction with the history of stem
cell transplant and known chronic GVHD involving 50% of the
body surface area, made the pathologist favor a diagnosis of
chronic GVHD involving the ICD. Allergic reaction was also
considered but was less favored, given the known history. In
our case, the patient had several risk factors for developing
chronic cutaneous GVHD overlying his device. This process
could have been the result of prior mantle radiation therapy, of
initial device placement, or of the device or device pocket itself.
We ﬁnd this case unique in that the reaction was localized to the
area overlying the device, and with implantation of the device
under the pectoralis as well as systemic steroid therapy, the
GVHD resolved. We believe that it is important to include
GVHD when cultures are negative and antibiotics have not
subsided symptoms, especially in a patient who has undergone
allogeneic hematopoietic cell transplantation. Chronic GVHD
can happen at any time post hematopoietic cell transplantation.8
In our review of the literature, we did not ﬁnd any reported
cases of GVHD that was caused by an ICD.References
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